Donor engraftment was monitored 8 16 weeks after transplantation by staining with antibody to CD45.2 and antibodies to lineage-specific antigens.
Donor engraftment was monitored 8 16 weeks after transplantation by staining with antibodies to CD45.2 and to individual lineage markers that included CD4, B220, Gr-1, or Ter119.
Assessment of tumour response was monitored 4 6 weeks after the beginning of combined therapy (CO-TH).
Fibrosis occurrence was monitored 4 weeks after initiation of BLM administration.
Outgrowth efficiency was monitored 8 weeks after transplantation by sacrificing non-pregnant recipients and staining mammary gland whole mounts as described above.
For example, researchers in Brisbane, Australia, and in Leeds, England, studied 58 sedentary overweight or obese men and women who participated in a closely monitored 12-week aerobic exercise program.
Participants in both groups carried out a standardised and monitored 12 week eccentric calf training programme.
All germinants in all plots were monitored 1 week after sowing and subsequently every 3 weeks until death or seed production.
For tumor regrowth studies, the size of the subcutaneous tumors was monitored 3 times a week.
Mice were monitored 3 times per week for tumor volume by caliper measurement.
